Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl.
Cinacalcet, a novel calcimimetic compound, is effective in reducing parathyroid hormone (PTH) levels in approximately 70% of patients with secondary hyperparathyroidism. However, interindividual variations in the dose required to achieve the treatment goal have been noted in clinical studies. Our investigation examined the genetic polymorphisms of the calcium-sensing receptor (CaSR) gene as one possible cause of the different responses to cinacalcet. We report data on seven end-stage renal failure patients who were treated with regular haemodialysis and who participated in clinical trials of cinacalcet. All patients had secondary hyperparathyroidism with baseline intact PTH (iPTH) levels greater than 600 pg/ml. Three patients were male and four female with a mean+/-SD age of 60+/-12 years. DNA was extracted from peripheral lymphocytes. An area in exon 7 of the CaSR gene was amplified by the polymerase chain reaction and sequenced. Mean+/-SD baseline iPTH was 1086+/-189 pg/ml. The five patients without Arg990Gly demonstrated a 29.7+/-4.0% (+/-SEM) reduction in iPTH from individual baseline. One patient was found to be homozygous for the Arg990Gly polymorphism and another was heterozygous for both arginine and glycine alleles. The homozygous patient showed a significantly higher sensitivity to cinacalcet compared to the other patients (P=0.003) with a 76.3+/-7.7% reduction in iPTH from baseline. No polymorphisms were noted in codons 986 or 1011. This preliminary study points to the possibility that patients homozygous for glycine at the 990 position in exon 7 of the CaSR may be more sensitive to the calcimimetic drug cinacalcet compared to those who are homozygous for arginine at that location.
Rothe
Hansjörg M
HM
Division of Nephrology and Hypertension, The Brookdale University Hospital and Medical Center, Brooklyn, New York 11212, USA. rothe@doctors.org.uk
Shapiro
Warren B
WB
Sun
Wei Y
WY
Chou
Shyan-Yih
SY
D000328:Adult; D000368:Aged; D000483:Alleles; D001120:Arginine / Q000235:genetics*; D001483:Base Sequence; D002118:Calcium / Q000378:metabolism*; D000069449:Cinacalcet; D002986:Clinical Trials as Topic; D004247:DNA / Q000378:metabolism; D005091:Exons; D005260:Female; D005838:Genotype; D005998:Glycine / Q000737:chemistry / Q000235:genetics*; D006720:Homozygote; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000235:genetics; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D008969:Molecular Sequence Data; D009281:Naphthalenes / Q000494:pharmacology*; D010597:Pharmacogenetics / Q000379:methods; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D044169:Receptors, Calcium-Sensing / Q000235:genetics*; D017422:Sequence Analysis, DNA; D013997:Time Factors
D009281:Naphthalenes; D044169:Receptors, Calcium-Sensing; D004247:DNA; D001120:Arginine; D002118:Calcium; D005998:Glycine; D000069449:Cinacalcet